Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497332 | 0.94 | BACE1 (0.55) | BACE1BACE2KISS1RTFPIERBB2 | |
| SCHEMBL31497394 | 0.92 | BACE1 (0.58) | BACE1BACE2TFPIERBB2 | |
| SCHEMBL31497390 | 0.90 | BACE1 (0.60) | BACE1BACE2KISS1RTFPIERBB2 | |
| SCHEMBL31497343 | 0.90 | BACE1 (0.60) | BACE1BACE2ERBB2 | |
| SCHEMBL31497324 | 0.88 | ERBB2 (0.48) | BACE1BACE2ERBB2PTPN1 | |
| SCHEMBL31497356 | 0.86 | BACE1 (0.65) | BACE1BACE2KISS1RTFPI | |
| SCHEMBL31497379 | 0.86 | ERBB2 (0.48) | BACE1BACE2ERBB2PTPN1 | |
| SCHEMBL31497319 | 0.86 | SIRT2 (0.47) | BACE1BACE2ERBB2PTPN1 | |
| SCHEMBL31497337 | 0.85 | ERBB2 (0.50) | BACE1BACE2ERBB2PTPN1 | |
| SCHEMBL31497334 | 0.84 | ERBB2 (0.49) | BACE1BACE2ERBB2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545551-A1 | PEPTIDE INHIBITOR AND USE THEREOF | Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd (CN) | 2025-04-30 | — | — | EP | disclosed |